Previous 10 | Next 10 |
2023-11-22 14:22:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through...
2023-11-18 12:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Developed in Partnership with Healthcare Professionals and Patients, Let’s Talk About LGSOC Provides Information Related to the Biology, Diagnosis, Treatment, and Patient Experience Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicine...
2023-11-12 01:40:08 ET Summary An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to keep avutometinib + defactinib for LGSC on the market...
2023-11-09 09:02:09 ET More on Verastem Verastem: Signs Of Life For A Beaten-Down Equity RAMPing Up Hope: Verastem's Cancer Crusade Verastem, China's GenFleet to collaborate on RAS pathway-driven cancer drugs For further details see: Verastem files $300M ...
2023-11-09 03:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-08 17:20:55 ET More on Verastem Verastem: Signs Of Life For A Beaten-Down Equity RAMPing Up Hope: Verastem's Cancer Crusade Verastem, China's GenFleet to collaborate on RAS pathway-driven cancer drugs Seeking Alpha’s Quant Rating on Verastem ...
Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024 Expects to Begin Enrollment in Phase 3 Confirmatory Trial, RAMP 301, of Avutometinib and Defactinib in LGSOC in Q4 2023 Presented Add...
Multiple Years for Diagnosis, Limited Treatment Options, Treatment Side Effects, and Cancer Recurrence Main Concerns of Respondents Survey Developed Through a Global Collaboration Among Patient Advocacy Groups and Medical Leaders to Uncover and Address the Urgent Needs of Patients ...
Planned Subgroup Analysis of RAMP 201 Data Showed Combination Demonstrated Robust Efficacy in Recurrent LGSOC Regardless of Number and Class of Prior Therapies Including After Poor Response to Prior Therapy Late-Breaking Abstract Featured as an Oral Presentation during a Plenary Session a...
News, Short Squeeze, Breakout and More Instantly...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000 ® and Russell Microcap ...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...